NCT05460533 - A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

Tisagenlecleucel

Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.

Trial Locations (6)

Memorial Sloan Kettering Cancer Center, New York

Johns Hopkins University (Data Collection Only), Baltimore

Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati

Children's Hospital Colorado (Data Collection Only), Aurora

Children's Hospital of Los Angeles (Data Collection Only), Los Angeles

Stanford University (Data Collection Only), Stanford